While the revenue and earnings per share (EPS) for Alnylam (ALNY) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
The Alnylam Pharmaceuticals Q4 2024 Earnings Conference Call is set to begin on February 13, 2025, at 08:30 AM ET. Key company participants include CEO Yvonne Greenstreet and CFO Jeff Poulton, among others. The call is currently in listen-only mode for all attendees.
We are concentrating on biotech stocks such as VRTX, GILD, BIIB, ALNY, and MRNA, which are set to announce their results this week.
In addition to looking at analysts' predictions for Alnylam's (ALNY) revenue and earnings, it's important to assess forecasts for some of its main metrics. This will help us understand how the company may have performed in the quarter that ended in December 2024.
Investors can increase their returns by including these highly-rated liquid stocks, such as Alnylam Pharmaceuticals, Frontdoor, EverQuote, and Sezzle, in their portfolios.
On January 27, 2024, ALNY, HBT, APH, GNTY, and OSUR were included in the Zacks Rank #1 (Strong Buy) List.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
On January 21, 2025, CDNA, AVXL, and ALNY were included in the Zacks Rank #1 (Strong Buy) list of momentum stocks.
Alnylam Pharmaceuticals is expected to see growth in 2025 due to its commercialization efforts and early-stage research. These factors are likely to play a significant role in the company's success.
This is a comparison of how Alnylam Pharmaceuticals (ALNY) and argenx SE (ARGX) have done in relation to their industry up to this point in the year.